Ticker
ACTI.ST

Price
0.94
Stock movement down
-0.01 (-1.26%)
Company name
Active Biotech AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Markedsværdi
248.20M
Ent værdi
209.60M
Pris/omsætning
-
Pris/bog
5.04
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-13.47%
3 års afkast
-28.72%
5 års afkast
-17.10%
10 års afkast
-29.73%
Senest opdateret: 2023-01-28

UDBYTTE

ACTI.ST betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning-
Pris til egenkapital5.04
EV i forhold til salg-

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier264.89M
EPS (TTM)-0.26
FCF pr. aktie (TTM)-0.25

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsindkomst (TTM)-57.60M
Nettoindkomst (TTM)-58.30M
EPS (TTM)-0.26
EPS (1 år frem)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter55.00M
Nettotilgodehavender3.80M
Omsætningsaktiver i alt58.80M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver65.60M
Kreditor0.00
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser12.00M
Sum gæld16.40M
Aktionærernes egenkapital49.20M
Materielle nettoaktiver49.00M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-56.87M
Investeringsudgifter (TTM)400.00K
Fri pengestrøm (TTM)-57.27M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-118.50%
Afkast af aktiver-88.87%
Afkast af investeret kapital-118.50%
Kontant afkast af investeret kapital-116.39%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.95
Daglig høj0.95
Daglig lav0.92
Daglig volumen57K
Højeste gennem alle tider321.94
1 års analytiker estimat2.80
Beta0.54
EPS (TTM)-0.26
Udbytte pr. aktie-
Ex-div dato17 Apr 1998
Næste dato for resultatpræsentation9 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACTI.STS&P500
Nuværende prisfald fra top notering-99.71%-15.08%
Højeste prisfald-99.73%-56.47%
Højeste efterår dato13 Oct 20229 Mar 2009
Gennemsnitlig fald fra toppen-91.41%-11.49%
Gennemsnitlig tid til nyt højdepunkt6526 days13 days
Maks. tid til nyt højdepunkt6525 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ACTI.ST (Active Biotech AB) company logo
Markedsværdi
248.20M
Markedsværdi kategori
Small-cap
Beskrivelse
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Personale
9
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Sweden
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
1. juni 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
19. maj 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...
18. maj 2022
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB...
28. april 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod ...
26. april 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active ...
21. april 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the M...
20. april 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, t...
31. marts 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK ...
25. marts 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular pr...
9. februar 2022
Næste side